The Association of High Dose Vasopressor and Delayed Vasopressor Titration with 28-Day Mortality in Adult Patients with Septic Shock
DOI:
https://doi.org/10.31584/jhsmr.2022886Keywords:
adult patients, factors, mortality, septic shock, Vasopressor dose, 28-day mortalityAbstract
Objective: This study aimed to investigate any association between vasopressor dose and mortality, and to identify factors independently associated with 28-day mortality in adult patients with septic shock.
Material and Methods: Adult septic shock patients admitted to internal medicine wards; from May 2018-November 2020, were retrospectively included. Collected data included: patient demographics and clinical characteristics, baseline vital signs, source of infection, vasopressor dose, treatment modalities and patient outcomes. The primary outcome was 28-day mortality.
Results: From 253 patients, 54.9% survived, and 45.1% died. Compared to survivors, non-survivors had a significantly higher median Acute Physiology and Chronic Health Evaluation II score, higher median baseline serum lactate level and required a higher median-maximum dose of vasopressor. Multivariate analysis showed the maximum dose of vasopressor >0.2 mcg/kg/min (odd ratio (OR): 2.91, 95% confidence interval (CI): 1.13-7.47; p-value=0.027), time to maximum dose of vasopressor after 24 hours (OR: 4.98, 95% Cl: 2.07-11.99; p-value<0.001), Sequential Organ Failure Assessment score >10 (OR: 2.92, 95% CI: 1.27-6.71; p-value=0.012), pneumonia (OR: 2.16, 95 %CI: 1.01-4.61; p-value=0.047) and receiving fluid resuscitation during the first 24 hours <3,000 mL (OR: 2.27, 95% CI: 1.05-4.89; p-value=0.037) to be independent predictors of 28-day mortality.
Conclusions: A higher intensity of vasopressor and longer time to maximum dose of vasopressor were found to be independent predictors of septic shock mortality.
References
World Health Organization. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020.
Auchet T, Regnier MA, Girerd N, Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care 2017;7:43.
Wilkman E, Kaukonen KM, Pettilä V, Kuitunen A, Varpula M. Association between inotrope treatment and 90-day mortality in patients with septic shock. Acta Anaesthesiol Scand 2013;57:431-42.
Tongyoo S, Chayakul C, Kanoknatsiwattana S, Permpikul C. Albumin versus gelatin solution for the treatment of refractory septic shock: a patient baseline-matched-cohort study. Siriraj Med J 2020;72:451-6.
Permpikul C, Tongyoo S, Ratanarat R, Wilachone W, Poompichet A. Impact of septic shock hemodynamic resuscitation guidelines on rapid early volume replacement and reduced mortality. J Med Assoc Thai 2010;93(Suppl 1):S102-9.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017;45:486-552.
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49:e1063-143.
Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). J Intensive Care 2021;9:53.
Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009;24:293-316.
Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early use of norepinephrine in septic shock resuscitation (CENSER). A randomized trial. Am J Respir Crit Care Med 2019;199:1097-105.
Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen JT, Phillips KM, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med 2020;48:1445-53. 12. Domizi R, Calcinaro S, Harris S, Beilstein C, Boerma C, Chiche JD, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care 2020;57:185-90.
Yamamura H, Kawazoe Y, Miyamoto K, Yamamoto T, Ohta Y, Morimoto T. Effect of norepinephrine dosage on mortality in patients with septic shock. J Intensive Care 2018;6:12.
Auchet T, Regnier MA, Girerd N, Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care 2017;7:43.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama 2016;315:801-10. 16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. Jama 2001;286:1754-8.
Goradia S, Sardaneh AA, Narayan SW, Penm J, Patanwala AE. Vasopressor dose equivalence: A scoping review and suggested formula. J Crit Care 2021;61:233-40.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:805-35.
Youden W. Index for rating diagnostic tests. Cancer 1950;3:32- 5.
Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med 2011;183:847-55.
Tongyoo S, Permpikul C, Haemin R, Epichath N. Predicting factors, incidence and prognosis of cardiac arrhythmia in medical, non-acute coronary syndrome, critically ill patients. J Med Assoc Thai 2013;96 (Suppl 2):S238-45.
Chayakul W, Tongyoo S, Permpikul C. Incidence and Outcomes of Sepsis-Related Cardiomyopathy: A Prospective Cohort Study. J Med Assoc Thai 2021;104:497-505.
Macdonald SPJ, Keijzers G, Taylor DM, Kinnear F, Arendts G, Fatovich DM, et al. Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): a pilot randomised controlled trial. Intensive Care Med 2018;44:2070-8.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
